Relmada Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Relmada Therapeutics wird ein Gewinn- und Umsatzwachstum von 5.2% bzw. 75.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 21.5% pro Jahr wachsen soll.

Wichtige Informationen

5.2%

Wachstumsrate der Gewinne

21.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	75.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	05 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Dec 07

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Dec 02

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Nov 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RLMD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	20	-131	-69	N/A	3
12/31/2025	N/A	-100	-65	N/A	3
12/31/2024	N/A	-82	-55	N/A	3
6/30/2024	N/A	-87	-48	-48	N/A
3/31/2024	N/A	-94	-48	-48	N/A
12/31/2023	N/A	-99	-52	-52	N/A
9/30/2023	N/A	-112	-77	-77	N/A
6/30/2023	N/A	-129	-93	-93	N/A
3/31/2023	N/A	-144	-101	-101	N/A
12/31/2022	N/A	-157	-104	-104	N/A
9/30/2022	N/A	-153	-106	-106	N/A
6/30/2022	N/A	-157	-100	-100	N/A
3/31/2022	N/A	-143	-95	-95	N/A
12/31/2021	N/A	-126	-92	-92	N/A
9/30/2021	N/A	-112	-61	-61	N/A
6/30/2021	N/A	-86	-53	-53	N/A
3/31/2021	N/A	-71	-40	-40	N/A
12/31/2020	N/A	-59	-28	-28	N/A
9/30/2020	N/A	-43	-25	-25	N/A
6/30/2020	N/A	-30	-15	-15	N/A
3/31/2020	N/A	-23	-14	-14	N/A
12/31/2019	N/A	-15	-12	-12	N/A
9/30/2019	N/A	-18	-11	-11	N/A
6/30/2019	N/A	-17	-10	-10	N/A
3/31/2019	N/A	-17	-9	-9	N/A
12/31/2018	N/A	-17	-9	-9	N/A
9/30/2018	N/A	-11	-7	-7	N/A
6/30/2018	N/A	-9	-6	-6	N/A
3/31/2018	N/A	-7	N/A	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	N/A	-6	N/A	-5	N/A
6/30/2017	N/A	-6	N/A	-6	N/A
3/31/2017	N/A	-8	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-10	N/A
9/30/2016	N/A	-9	N/A	-12	N/A
6/30/2016	N/A	-3	N/A	-13	N/A
3/31/2016	N/A	6	N/A	-15	N/A
12/31/2015	N/A	6	N/A	-16	N/A
9/30/2015	N/A	14	N/A	-17	N/A
6/30/2015	N/A	-21	N/A	-16	N/A
3/31/2015	N/A	-55	N/A	-13	N/A
12/31/2014	N/A	-46	N/A	-9	N/A
9/30/2014	N/A	-56	N/A	-5	N/A
6/30/2014	N/A	-28	N/A	-3	N/A
3/31/2014	N/A	-13	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RLMD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RLMD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RLMD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RLMD wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: RLMD wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RLMD in 3 Jahren voraussichtlich hoch sein wird

Relmada Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 18% to US$12.50

Price target increased by 13% to US$12.33

Price target increased by 24% to US$13.50

Price target increased by 30% to US$13.50

Price target increased by 24% to US$12.83

Price target increased by 19% to US$12.67

Recent updates

Relmada Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 18% to US$12.50

CEO & Director recently bought US$395k worth of stock

New major risk - Share price stability

New major risk - Revenue and earnings growth

Price target increased by 13% to US$12.33

Relmada Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Price target increased by 24% to US$13.50

Price target increased by 30% to US$13.50

Relmada Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Relmada Therapeutics, Inc., Annual General Meeting, May 24, 2024

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Relmada Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

New major risk - Share price stability

CEO & Director recently bought US$387k worth of stock

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Price target increased by 24% to US$12.83

Relmada Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder

Price target increased by 19% to US$12.67

New major risk - Revenue and earnings growth

Relmada Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Comp Value Index

Relmada Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors

Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

CEO & Director recently bought US$116k worth of stock

Relmada Therapeutics, Inc. Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

Price target decreased to US$17.42

High number of new and inexperienced directors

Price target decreased to US$17.42

Relmada Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Relmada Therapeutics Inc. Announces Top-line Results from Phase 3 RELIANCE III Trial for REL 1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Price target increased to US$66.00

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance III Trial for REL-1017 as A Monotherapy for Major Depressive Disorder

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Relmada Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Relmada Therapeutics, Inc. Appoints John Hixon as Head of Commercial

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

CEO & Director exercised options and sold US$83k worth of stock

Relmada Therapeutics, Inc. Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

High number of new and inexperienced directors

Relmada Therapeutics, Inc., Annual General Meeting, May 25, 2022

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 VS Ketamine for Abuse Potential

4 Clinical Catalysts On Tap For Relmada In 2022

Relmada Therapeutics, Inc. Announces Publication of Rel-1017 Phase 2 Study Results in the American Journal of Psychiatry

Price target decreased to US$65.86

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Independent Chairman of the Board notifies of intention to sell stock

Price target increased to US$70.80

Independent Chairman of the Board notifies of intention to sell stock

Our First Look At Relmada Therapeutics

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Independent Chairman of the Board notifies of intention to sell stock

Price target increased to US$69.50

Independent Chairman of the Board notifies of intention to sell stock

Relmada Therapeutics, Inc. Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

Independent Chairman of the Board notifies of intention to sell stock

Relmada Therapeutics, Inc. to Report Q4, 2020 Results on Mar 23, 2021